TY - JOUR
T1 - Omics technologies in allergy and asthma research
T2 - An EAACI position paper
AU - Radzikowska, Urszula
AU - Baerenfaller, Katja
AU - Cornejo-Garcia, José Antonio
AU - Karaaslan, Cagatay
AU - Barletta, Elena
AU - Sarac, Basak Ezgi
AU - Zhakparov, Damir
AU - Villaseñor, Alma
AU - Eguiluz-Gracia, Ibon
AU - Mayorga, Cristobalina
AU - Sokolowska, Milena
AU - Barbas, Coral
AU - Barber, Domingo
AU - Ollert, Markus
AU - Chivato, Tomas
AU - Agache, Ioana
AU - Escribese, Maria M.
N1 - Funding Information:
AV is a Secretary of the EAACI IG on Allergy Diagnosis & Systems Medicine. CK is a member of the EAACI working group Genomics and Proteomics. IA is an Associate Editor of Allergy and CTA. KB reports: The Center for Precision Proteomics providing partial salary funding is funded through the Swiss canton of Grisons. Salary payments are made through the institution and are part of the regular salary. KB has been funded by the Earth Vision nonprofit corporation for chairing an event, performing a study and manuscript writing. The funding has been made to SIAF; the resulting manuscript has been published https://doi.org/10.3390/microorganisms8040498; the topic has no overlap with the study presented here. KB is a member of the board of directors of the Swiss Institute of Bioinformatics, member of the EAACI working group Genomics and Proteomics and president of the bioinformatics intersection of LS2 and member of LS2. MME is a Chair of EAACI WG on Genomics and Proteomics and report lecture fees from Diater and Stallergenes. MS reports grants from SNSF, GSK, Novartis; payments from AstraZeneca, and position of European Academy of Allergy and Clinical Immunology (EAACI) Basic and Clinical Immunology Board Secretary. MO reports personal consulting honoraria received from Hycor Biomedical; Member‐at‐Large 2019‐2022, Executive Committee, European Academy of Allergy and Clinical Immunology (EAACI). UR is a Secretary of the EAACI WG on Genomics and Proteomics. All other authors report no conflict of interest regarding this manuscript.
Publisher Copyright:
© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2022/10
Y1 - 2022/10
N2 - Allergic diseases and asthma are heterogenous chronic inflammatory conditions with several distinct complex endotypes. Both environmental and genetic factors can influence the development and progression of allergy. Complex pathogenetic pathways observed in allergic disorders present a challenge in patient management and successful targeted treatment strategies. The increasing availability of high-throughput omics technologies, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics allows studying biochemical systems and pathophysiological processes underlying allergic responses. Additionally, omics techniques present clinical applicability by functional identification and validation of biomarkers. Therefore, finding molecules or patterns characteristic for distinct immune-inflammatory endotypes, can subsequently influence its development, progression, and treatment. There is a great potential to further increase the effectiveness of single omics approaches by integrating them with other omics, and nonomics data. Systems biology aims to simultaneously and longitudinally understand multiple layers of a complex and multifactorial disease, such as allergy, or asthma by integrating several, separated data sets and generating a complete molecular profile of the condition. With the use of sophisticated biostatistics and machine learning techniques, these approaches provide in-depth insight into individual biological systems and will allow efficient and customized healthcare approaches, called precision medicine. In this EAACI Position Paper, the Task Force “Omics technologies in allergic research” broadly reviewed current advances and applicability of omics techniques in allergic diseases and asthma research, with a focus on methodology and data analysis, aiming to provide researchers (basic and clinical) with a desk reference in the field. The potential of omics strategies in understanding disease pathophysiology and key tools to reach unmet needs in allergy precision medicine, such as successful patients’ stratification, accurate disease prognosis, and prediction of treatment efficacy and successful prevention measures are highlighted.
AB - Allergic diseases and asthma are heterogenous chronic inflammatory conditions with several distinct complex endotypes. Both environmental and genetic factors can influence the development and progression of allergy. Complex pathogenetic pathways observed in allergic disorders present a challenge in patient management and successful targeted treatment strategies. The increasing availability of high-throughput omics technologies, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics allows studying biochemical systems and pathophysiological processes underlying allergic responses. Additionally, omics techniques present clinical applicability by functional identification and validation of biomarkers. Therefore, finding molecules or patterns characteristic for distinct immune-inflammatory endotypes, can subsequently influence its development, progression, and treatment. There is a great potential to further increase the effectiveness of single omics approaches by integrating them with other omics, and nonomics data. Systems biology aims to simultaneously and longitudinally understand multiple layers of a complex and multifactorial disease, such as allergy, or asthma by integrating several, separated data sets and generating a complete molecular profile of the condition. With the use of sophisticated biostatistics and machine learning techniques, these approaches provide in-depth insight into individual biological systems and will allow efficient and customized healthcare approaches, called precision medicine. In this EAACI Position Paper, the Task Force “Omics technologies in allergic research” broadly reviewed current advances and applicability of omics techniques in allergic diseases and asthma research, with a focus on methodology and data analysis, aiming to provide researchers (basic and clinical) with a desk reference in the field. The potential of omics strategies in understanding disease pathophysiology and key tools to reach unmet needs in allergy precision medicine, such as successful patients’ stratification, accurate disease prognosis, and prediction of treatment efficacy and successful prevention measures are highlighted.
KW - allergy
KW - biomarker
KW - omic
KW - precision medicine
KW - systems biology
UR - http://www.scopus.com/inward/record.url?scp=85133037361&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/35713644
U2 - 10.1111/all.15412
DO - 10.1111/all.15412
M3 - Article
C2 - 35713644
AN - SCOPUS:85133037361
SN - 0105-4538
VL - 77
SP - 2888
EP - 2908
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 10
ER -